High-dose chemotherapy: is it standard management for any common solid tumor? (Q33787443)

29 July 2017

1 reference

title

High-dose chemotherapy: is it standard management for any common solid tumor? (English)

1 reference

29 July 2017

1 reference

M MacNeil

1

1 reference

29 July 2017

E A Eisenhauer

series ordinal

2

1 reference

29 July 2017

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

1145-1161

1 reference

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Bone marrow autotransplantation for solid tumors--prospects

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-response in the treatment of breast cancer: a critical review

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose chemotherapy in solid tumours. A review of published data in selected tumours with a commentary.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose intensification and breast cancer: current results and future perspectives

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Management and survival of female breast cancer: results of a national survey by the American College of Surgeons

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Inflammatory breast cancer: a review

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Second-line chemotherapy for recurrent carcinoma of the ovary.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Advanced ovarian cancer. Drug resistance, supportive care and dose intensity.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

How many more nails to seal the coffin of dose intensity?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-intensity in ovarian carcinoma: hold, enough?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Chemotherapy of lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Dose-intensive therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008346316225

7 January 2021

Identifiers

DOI

10.1023/A:1008346316225

1 reference

29 July 2017

1 reference